OncoMatch/Lung Cancer — Small Cell (SCLC)/BRCA2
Lung Cancer — Small Cell (SCLC)BRCA2 Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
BRCA2 alterations occur in a small subset of SCLC and represent a potential marker of PARP inhibitor sensitivity through homologous recombination deficiency. PARP inhibitors have shown preclinical activity in BRCA2-deficient SCLC models. Trials study PARP inhibitor combinations and maintenance strategies in HRD-selected extensive-stage SCLC including BRCA2-mutant cases.
Top recruiting
Top recruiting BRCA2 Lung Cancer — Small Cell (SCLC) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Lung Cancer — Small Cell (SCLC) biomarkers
Browse other molecular targets with active Lung Cancer — Small Cell (SCLC) trials.